Emerging new Company veriNOS pharmaceuticals, established in October 2022, Led by CEO, Christian Wandersee and CMO Professor John Stover, provides an update on its revival of late-stage drug candidate ronopterin for the treatment of Traumatic Brain Injury (TBI). Ronopterin is the first and only iNOS inhibitor which has demonstrated repeated signs of neuroprotection in TBI […]